Frankfurt - Delayed Quote EUR

Xvivo Perfusion AB (publ) (3XV.F)

28.18
-0.26
(-0.91%)
At close: May 30 at 8:05:44 AM GMT+2
Loading Chart for 3XV.F
  • Previous Close 28.44
  • Open 28.18
  • Bid 27.76 x --
  • Ask 28.24 x --
  • Day's Range 28.18 - 28.18
  • 52 Week Range 22.34 - 46.80
  • Volume 9
  • Avg. Volume 16
  • Market Cap (intraday) 888.234M
  • Beta (5Y Monthly) 1.98
  • PE Ratio (TTM) 70.45
  • EPS (TTM) 0.40
  • Earnings Date Jul 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.

www.xvivogroup.com

193

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 3XV.F

View More

Performance Overview: 3XV.F

Trailing total returns as of 5/30/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

3XV.F
33.14%
OMX Stockholm 30 Index (^OMX)
0.52%

1-Year Return

3XV.F
21.83%
OMX Stockholm 30 Index (^OMX)
3.74%

3-Year Return

3XV.F
24.14%
OMX Stockholm 30 Index (^OMX)
20.27%

5-Year Return

3XV.F
67.74%
OMX Stockholm 30 Index (^OMX)
53.15%

Compare To: 3XV.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 3XV.F

View More

Valuation Measures

Annual
As of 5/30/2025
  • Market Cap

    888.23M

  • Enterprise Value

    861.86M

  • Trailing P/E

    70.72

  • Forward P/E

    77.52

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.35

  • Price/Book (mrq)

    4.61

  • Enterprise Value/Revenue

    10.95

  • Enterprise Value/EBITDA

    44.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.02%

  • Return on Assets (ttm)

    2.67%

  • Return on Equity (ttm)

    6.69%

  • Revenue (ttm)

    854.98M

  • Net Income Avi to Common (ttm)

    137M

  • Diluted EPS (ttm)

    0.40

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    315.87M

  • Total Debt/Equity (mrq)

    1.40%

  • Levered Free Cash Flow (ttm)

    -169.35M

Research Analysis: 3XV.F

View More

Company Insights: 3XV.F

Research Reports: 3XV.F

View More

People Also Watch